Lifecore Biomedical/$LFCR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lifecore Biomedical
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Ticker
$LFCR
Sector
Primary listing
Employees
406
Headquarters
Website
LFCR Metrics
BasicAdvanced
$296M
-
-$1.27
0.61
-
Price and volume
Market cap
$296M
Beta
0.61
52-week high
$8.98
52-week low
$4.76
Average daily volume
131K
Financial strength
Current ratio
2.839
Quick ratio
1.456
Long term debt to equity
267.744
Total debt to equity
275.806
Interest coverage (TTM)
-0.55%
Profitability
EBITDA (TTM)
-3.979
Gross margin (TTM)
31.27%
Net profit margin (TTM)
-30.04%
Operating margin (TTM)
-9.32%
Effective tax rate (TTM)
-0.11%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
-3.04%
Return on equity (TTM)
-76.41%
Valuation
Price to revenue (TTM)
2.135
Price to book
218.95
Price to tangible book (TTM)
-17.47
Price to free cash flow (TTM)
-20.195
Free cash flow yield (TTM)
-4.95%
Free cash flow per share (TTM)
-0.391
Growth
Revenue change (TTM)
0.47%
Earnings per share change (TTM)
-482.39%
3-year revenue growth (CAGR)
5.02%
10-year revenue growth (CAGR)
-13.34%
3-year earnings per share growth (CAGR)
-31.51%
10-year earnings per share growth (CAGR)
9.80%
What the Analysts think about LFCR
Analyst ratings (Buy, Hold, Sell) for Lifecore Biomedical stock.
LFCR Financial Performance
Revenues and expenses
LFCR Earnings Performance
Company profitability
LFCR News
AllArticlesVideos
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Settles
Newsfile Corp·3 weeks ago
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement
Newsfile Corp·4 weeks ago
Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lifecore Biomedical stock?
Lifecore Biomedical (LFCR) has a market cap of $296M as of February 05, 2026.
What is the P/E ratio for Lifecore Biomedical stock?
The price to earnings (P/E) ratio for Lifecore Biomedical (LFCR) stock is 0 as of February 05, 2026.
Does Lifecore Biomedical stock pay dividends?
No, Lifecore Biomedical (LFCR) stock does not pay dividends to its shareholders as of February 05, 2026.
When is the next Lifecore Biomedical dividend payment date?
Lifecore Biomedical (LFCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Lifecore Biomedical?
Lifecore Biomedical (LFCR) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.